HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons
The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia in...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/full |
| _version_ | 1818408075218911232 |
|---|---|
| author | Andrey A. Poloznikov Stepan A. Nersisyan Dmitry M. Hushpulian Dmitry M. Hushpulian Eliot H. Kazakov Alexander G. Tonevitsky Sergey V. Kazakov Valery I. Vechorko Sergey V. Nikulin Julia A. Makarova Irina G. Gazaryan Irina G. Gazaryan Irina G. Gazaryan Irina G. Gazaryan |
| author_facet | Andrey A. Poloznikov Stepan A. Nersisyan Dmitry M. Hushpulian Dmitry M. Hushpulian Eliot H. Kazakov Alexander G. Tonevitsky Sergey V. Kazakov Valery I. Vechorko Sergey V. Nikulin Julia A. Makarova Irina G. Gazaryan Irina G. Gazaryan Irina G. Gazaryan Irina G. Gazaryan |
| author_sort | Andrey A. Poloznikov |
| collection | DOAJ |
| description | The review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection. |
| first_indexed | 2024-12-14T09:37:58Z |
| format | Article |
| id | doaj.art-861906911e074ab98b8dd5ba057316b3 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T09:37:58Z |
| publishDate | 2021-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-861906911e074ab98b8dd5ba057316b32022-12-21T23:07:53ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-01-011110.3389/fphar.2020.621054621054HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and ConsAndrey A. Poloznikov0Stepan A. Nersisyan1Dmitry M. Hushpulian2Dmitry M. Hushpulian3Eliot H. Kazakov4Alexander G. Tonevitsky5Sergey V. Kazakov6Valery I. Vechorko7Sergey V. Nikulin8Julia A. Makarova9Irina G. Gazaryan10Irina G. Gazaryan11Irina G. Gazaryan12Irina G. Gazaryan13Faculty of Biology and Biotechnology, HSE University, Moscow, RussiaFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaP. A. Hertsen Moscow Oncology Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, RussiaSchool of Biomedicine, Far Eastern Federal University, Vladivostok, RussiaDepartment of Anatomy and Cell Biology, New York Medical College, Valhalla, NY, United StatesFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaDepartment of Chemistry and Physical Sciences, Dyson College of Arts and Sciences, Pace University, Pleasantville, NY, United StatesCity Clinical Hospital No 15 Named After O. M. Filatov, Moscow, RussiaFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaFaculty of Biology and Biotechnology, HSE University, Moscow, RussiaP. A. Hertsen Moscow Oncology Research Center, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, RussiaDepartment of Anatomy and Cell Biology, New York Medical College, Valhalla, NY, United StatesDepartment of Chemistry and Physical Sciences, Dyson College of Arts and Sciences, Pace University, Pleasantville, NY, United StatesChemical Enzymology Department, M. V. Lomonosov Moscow State University, Moscow, RussiaThe review analyzes the potential advantages and problems associated with using HIF prolyl hydroxylase inhibitors as a treatment for COVID-19. HIF prolyl hydroxylase inhibitors are known to boost endogenous erythropoietin (Epo) and activate erythropoiesis by stabilizing and activating the hypoxia inducible factor (HIF). Recombinant Epo treatment has anti-inflammatory and healing properties, and thus, very likely, will be beneficial for moderate to severe cases of COVID-19. However, HIF PHD inhibition may have a significantly broader effect, in addition to stimulating the endogenous Epo production. The analysis of HIF target genes reveals that some HIF-targets, such as furin, could play a negative role with respect to viral entry. On the other hand, HIF prolyl hydroxylase inhibitors counteract ferroptosis, the process recently implicated in vessel damage during the later stages of COVID-19. Therefore, HIF prolyl hydroxylase inhibitors may serve as a promising treatment of COVID-19 complications, but they are unlikely to aid in the prevention of the initial stages of infection.https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/fullSARS-CoVhypoxia inducible factorroxadustatvadadustatadaptaquinneuradapt |
| spellingShingle | Andrey A. Poloznikov Stepan A. Nersisyan Dmitry M. Hushpulian Dmitry M. Hushpulian Eliot H. Kazakov Alexander G. Tonevitsky Sergey V. Kazakov Valery I. Vechorko Sergey V. Nikulin Julia A. Makarova Irina G. Gazaryan Irina G. Gazaryan Irina G. Gazaryan Irina G. Gazaryan HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons Frontiers in Pharmacology SARS-CoV hypoxia inducible factor roxadustat vadadustat adaptaquin neuradapt |
| title | HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons |
| title_full | HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons |
| title_fullStr | HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons |
| title_full_unstemmed | HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons |
| title_short | HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons |
| title_sort | hif prolyl hydroxylase inhibitors for covid 19 treatment pros and cons |
| topic | SARS-CoV hypoxia inducible factor roxadustat vadadustat adaptaquin neuradapt |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2020.621054/full |
| work_keys_str_mv | AT andreyapoloznikov hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT stepananersisyan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT dmitrymhushpulian hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT dmitrymhushpulian hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT eliothkazakov hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT alexandergtonevitsky hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT sergeyvkazakov hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT valeryivechorko hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT sergeyvnikulin hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT juliaamakarova hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons AT irinaggazaryan hifprolylhydroxylaseinhibitorsforcovid19treatmentprosandcons |